It has been demonstrated that patients with DRESS related to sulfonamides have, in many cases, a high incidence of slow acetylators carrier status (low N-acetylation), which determines N-acetyl-transferase deficiency, resulting in the formation of excessive amounts of hydroxylamine metabolites, which reach toxic levels and are capable of causing cell damage and immune activation.19 In Taiwanese, Japanese and Malaysian populations, a CYP2C9*3 gene variant (capable of reducing phenytoin excretion) is frequently found and is especially associated with DRESS triggered by this medication use
the worldwide 5-year median survival rate at 50% of cases, with the hypopharynx experiencing the worst outcomes [2]
Well, its certainly disruptive, but the solution, from the insurers perspectives, is clear: Raise the cost of coverage, or at least the cost of insurance plans that cover these drugs
Youve seen the headlines
Customer Support & Reviews Noom's patient support is one of its strongest areas
